APLS
Apellis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$41.03
+0.00%Margins
Gross margin
90.1%
EBITDA margin
16.0%
EBIT margin
14.9%
Net margin
12.1%
FCF margin
3.4%
32.1%
Return on equity
12.3%
Return on assets
18.6%
Return on invested capital
1.02x
Asset turnover
$37.8M
Cash from operations
$3.18
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026